ADVERTISEMENT
Hydrozid®
Hydrozid is a Danish-designed, FDA-cleared device for the in-office treatment of over 17 types of benign skin lesions. Hydrozid provides clinicians with a powerful, easy-to-use, off-the-shelf system offering superior accuracy & limited side effects. Disposable as normal waste, Hydrozid has a 3 year shelf life.
BDSC Company
BDSC Company
Hydrozid is a portable aerosol cryosurgery device, intended for topic use for the treatment of benign and premalignant skin lesions, including verruca (warts), plantar warts, seborrheic keratosis, actinic keratosis, achrochordon (skin tags), molluscum contagiosum, age spots (lentigo), dermatofibroma, small keloids, granuloma annulare, porokeratosis plantaris, angiomas, keratoacanthoma, chondrodermatitis, epithelial nevus, leukoplakia, granuloma pyogenicum, and pyogenic granuloma, by spraying a cryogen to freeze the compromised cells up to destruction.
Hydrozid is intended for professional use only.
Cryotherapy is significantly effective for a large number of benign skin problems including skin lesions. Advantages of cryotherapy:
- Short or no preparation time
- Fast wound healing
- Minimal risk of infection
- Aesthetic cosmetic results
Intended as cryotherapy for warts, skin lesions, and selected mucosal lesions.
Precautions for safe handling: No special measures required.
Information about fire - and explosion protection: No special measures required.
Conditions for safe storage, including any incompatibilities:
Storage: Store vertically.
Requirements to be met by storage rooms and receptacles: Do not expose to direct sunlight. Do
not expose to temperatures exceeding 50°C/122°F.
Information about storage in one common storage facility: Not required.
Further information about storage conditions: None.
Specific end use(s): Cryosurgery and cryotherapy.